PuriCore secures two patents for immunomodulatory technology

AIM-listed biopharma hopeful Puricore has been granted two US patents covering the technique for producing its 'immunomodulatory' therapy for inflammatory skin disorders.

Puricore, which has developed proprietary immunomodulatory formulations that reduce the immune reaction and can act as anti-inflammatory agents, said it also remained on track for a first-quarter filing of its investigational new drug (IND) application with the US regulator for its most advanced treatment, the PR022 programme in atopic dermatitis remains.

The patents, numbered 9,381,214 and 9,414,584 and expiring in 2032, cover methods of production, formulations and method of use of hypochlorous acid at therapeutic drug concentrations for the treatment of a broad range of inflammatory skin diseases, including atopic dermatitis.

"The issuance of these new patents is further evidence of the progress we have made in advancing our new strategic focus as an emerging specialty pharmaceutical company," said chief executive officer Alex Martin.

"We are continuing to invest in this platform technology and have additional patents, both issued and pending applications, which further support our development plans."